A great example of how markets can be transiently insane. A key question relating to combining amylin with GLP1 analogues is whether the long term tolerability will be enhanced wrt Semaglutide or tirzepatide. It’s far too early to say
Reposted from
Giles Yeo
Novo's CagriSema achieves 22.7% (!!) weight-loss as opposed to an expected 25% & the market goes into meltdown. Wow... a completely crazy response & shows the normalisation of expectations for these drugs. Completely unthinkable even 5 yrs ago! www.reuters.com/business/hea...
Comments